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Purpose: Temporal lobe epilepsy (TLE) is the most common variety of focal epilepsy among adults. The
neuroinﬂammatory mechanisms of epilepsies may be involved in the genesis of seizures and refractory
epilepsies, particularly in the case of progressive syndromes such as TLE associated with mesial
hippocampal sclerosis (TLE-HS). The goal of the present study is investigate the genetic proﬁle of
susceptibility of individuals with TLE-HS by analyzing the possible association of TLE-HS with human
leukocyte antigen (HLA) DRB1, DQA1 and DQB1 alleles.
Methods: Peripheral blood samples were collected from 42 individuals with pharmacoresistant TLE-HS
and 89 healthy controls. The typing of the HLA class II alleles from DRB1, DQB1, and DQA1 loci were
analyzed using sequence-speciﬁc primer-polymerase chain reaction (SSP-PCR) and identiﬁed through
sequencing. Statistical analysis of relative allele frequencies was performed using an Excel spreadsheet;
p-value, relative risk (RR), and odds ratio (OR) were calculated using the software Epi Info 6.0. p-values
<0.05 following Bonferroni’s method correction were considered statistically signiﬁcant.
Results: HLA-DRB1*13:02 was the only allele with a statistically signiﬁcant difference (p = 0.01) in
frequency between patients and controls. However, the signiﬁcance was lost following Bonferroni’s
method correction (p = 0.44). The remainder of the alleles in the HLA-DRB1, HLA-DQB1 and HLA-DQA1
regions did not exhibit any signiﬁcant association.
Conclusion: The allele HLA DRB1*13:02 has exhibited a tendency to behave as a susceptibility factor for
TLE-HS.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Temporal lobe epilepsy (TLE) is the most common epileptic
syndrome among adults and accounts for approximately 40% of
epilepsy cases and 60% of the ones with focal onset epilepsy
[1,22]. Hippocampal sclerosis is associated with TLE and is present
in 70–80% of the individuals with this type of epilepsy [1–4].
Epileptic episodes begin in childhood, adolescence or adult-
hood, but onset most frequently occurs between the ages of 10 and* Corresponding author at: Federal University of Rio de Janeiro State (UNIRIO) –
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febrile seizures in childhood before development of mesial
temporal lobe epilepsy [5]. Several etiologies have been attributed
to the cause of brain injury leading to progressive gliosis of the
temporal lobe, known as initial precipitating incidents (IPIs)
[6,7]. TLE-HS is clinically relevant due to its high prevalence as well
as to the high proportion of patients with seizures that are
refractory to pharmacological treatment.
Hippocampal sclerosis (HS) is one of the causes of this condition
and is present in 50–70% of patients with pharmacoresistant TLE
[8,9]. Neuroinﬂammatory ﬁndings have been described as a
associated to the onset of seizures and refractory epilepsies,
particularly in the case of progressive syndromes such as TLE-HS
[10]. Vezzani and Granata [16], demonstrated the participation ofserved.
Table 1
Distribution of alleles in the HLA CLASS II DRB1 region identiﬁed by the low-
resolution system.
Allele Patients
(N = 42)
FR% Controls
(N = 89)
FR% p-value RR OR
DRB1*01 07 8.33 12 6.74 0.62 1.18 1.28
DRB1*03 07 8.33 15 8.42 0.97 0.99 0.99
DRB1*04 12 14.28 23 12.92 0.74 1.10 1.15
DRB1*07 02 2.38 02 1.12 0.43 1.59 2.17
DRB1*08 05 5.95 13 7.30 0.67 0.85 0.79
DRB1*09 0 0 02 1.12 0.32 IND IND
DRB1*10 0 0 01 0.56 0.49 IND IND
DRB1*11 05 5.95 18 10.11 0.73 0.89 0.85
DRB1*12 09 10.71 10 5.61 0.12 1.61 2.15
DRB1*13 11 13.09 16 8.98 0.16 1.47 1.83
DRB1*14 05 5.95 22 12.35 0.09 0.52 0.41
DRB1*15 12 14.28 23 12.92 0.74 1.10 1.15
DRB1*16 09 10.71 21 11.79 0.78 0.92 0.88
Total 84 178
Caption: RR = relative risk, OD = odds ratio, IND = indeﬁnite.
Table 2
Distribution of alleles in the HLA CLASS II DQB1 region identiﬁed by the low-
resolution system.
Allele Patients
(N = 42)
FR% Controls
(N = 89)
FR% p-value RR OR
DQB1*02 10 11.94 25 14.04 0.60 0.86 0.80
DQB1*03 17 20.23 29 16.29 0.37 1.26 1.41
DQB1*04 16 19.04 26 14.60 0.30 1.30 1.49
DQB1*05 18 21.42 38 21.34 0.98 1.0 1.01
DQB1*06 23 27.38 60 33.70 0.16 0.70 0.59
Total 84 178
Caption: RR = relative risk, OD = odds ratio.
Table 3
Distribution of alleles in the HLA CLASS II DQA1 region identiﬁed by the low-
resolution system.
Allele Patients
(N = 42)
FR% Controls
(N = 89)
FR% p-value RR OR
DQA1*01 34 40.47 53 29.77 0.06 1.73 2.17
DQA1*02 12 14.28 17 9.55 0.35 1.31 1.50
DQA1*03 08 9.52 24 13.48 0.32 0.73 0.64
DQA1*04 08 9.52 23 12.92 0.24
0.67
0.57
DQA1*05 22 26.19 61 34.26 0.07 0.64 0.50
Total 84 178
Caption: RR = relative risk, OD = odds ratio.
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the activation of astrocytes through lesions of the blood-brain
barrier (BBB). Recently, we have shown that the levels of tumor
necrosis factor alpha (TNF-a), a highly relevant proinﬂammatory
cytokine, were reduced in patients with TLE-HS subjected to
surgical treatment [11–13], found that the number of macrophages
in microglial cells was higher in human leukocyte antigen-D
related (HLA-DR)-labeled human hippocampi surgically removed
from patients with TLE-HS compared with controls. Ozkara et al.
[14], found an association of HLA-DR4, HLA-DQ2 and HLA-DR7
with TLE-HS. Together, these ﬁndings indicate the possible
participation of genes involved in immune response in the
susceptibility to neuroinﬂammatory diseases, including TLE-HS.
The aim of the present study was to investigate the possible
genetic susceptibility of patients with TLE-HS associated with the
HLA class II DRB1, DQA1 and DQB1 alleles.
2. Materials and methods
Samples of peripheral blood were collected from 42 individuals
(22 females (52.36%) and 20 males (47.64%)) aged 15–65 years old
(mean = 42.8 years old) who met the diagnostic criteria for
pharmacoresistant TLE-HS at the Epilepsy Center of the Clem-
entino Fraga Filho University Federal Hospital (Federal University
of Rio de Janeiro/Universidade Federal do Rio de Janeiro – UFRJ)
and 89 age- and gender-matched healthy controls (47 females
(52.8%) and 42 males (47.2%)).
DNA was extracted by organic method using phenol:cloro-
phorm:isoamyl alcohol (25:24:1) and quantiﬁed in the NanoDrop
Lite Spectrophotometer (Thermo Fisher Scientiﬁc). The expression
and typing of the HLA class II alleles from DRB1, DQB1, and DQA1
loci in patients and controls were analyzed by sequence-speciﬁc
primer-polymerase chain reaction (SSP-PCR) and identiﬁed by
high- and low-resolution speciﬁc sequencing using a One Lambda
kit (Canoga Park, CA, USA) following the manufacturer’s recom-
mendations.
Statistical analysis of the relative allele frequencies was
performed using an Excel spreadsheet; p-value, relative risk (RR)
and odds ratio (OR) were calculated using the software Epi Info 6.0.
p-values <0.05 following Bonferroni correction were considered to
be statistically signiﬁcant.
According to the study protocol that was approved by the
institutional ethics committee, all of the participants were provided
due information as to the use of their clinical and genetic
information, and information, and have signed the informed.
3. Results
A signiﬁcant genetic association was not found when the
frequencies of the allelic regions were compared between patients
and controls relative to the HLA-DRB1, HLA-DQB1 and HLA-DQA1
regions identiﬁed using the low-resolution system (Tables 1–3).
Only the difference in the frequency of allele HLA-DRB1*13:02
was signiﬁcant between patients and controls (p = 0.01). However,
this frequency lost signiﬁcance following Bonferroni correction
(p = 0.44). The RR of the allele was 0.29. The frequency of the
remainder of the HLA-DRB1 alleles did not differ between patients
and controls, even in the case of the DRB1*15:03 allele, which was
the most frequent and was detected in seven patients (Table 4).
The HLA-DQB1*04:01 allele was the most frequent and was
detected in 10 patients. However, neither its frequency nor that
of the other HLA-DQB1 alleles exhibited a signiﬁcant difference
between patients and controls (Table 5).
The HLA-DQA1*05:01 allele was the most frequent in both
groups, but neither its frequency nor that of the other DQA1 allelesexhibited a signiﬁcant difference between patients and controls
(Table 6).
4. Discussion
Studies on inﬂammatory mechanisms and their relationship
with diseases of the central nervous system have been consistently
relevant in the epilepsy ﬁeld in the last decade. Neuroinﬂamma-
tory mechanisms appear to be a common and crucial component of
the pathogenesis of epilepsy and its resistency to pharmacological
treatment [10,15,16]. In the hippocampal samples surgically
removed from patients with TLE, Ravizza et al. [12,13] found
increased HLA-DR expression and macrophage inﬁltrates in the
microglial cells and increased IL-1b expression in the astrocytic
Table 4
Distribution of HLA-DRB1 alleles identiﬁed by the high-resolution system.
Allele Patients (N = 42) FR% Controls
(N = 89)
FR% p-value B RR OR
*01:01 2 2.32 3 1.68 0.69 0.88 0.7
*01:02 1 1.19 3 1.68 0.75 1.11 1.43
*01:03 4 4.76 6 3.37 0.57 0.87 0.69
*03:01 5 5.95 6 3.37 0.32 0.79 0.53
*03:05 2 2.32 6 3.37 0.65 1.11 1.45
*03:08 0 0.0 3 1.68 0.22 1.49 IND
*04:02 2 2.32 6 3.36 0.65 1.11 1.45
*04:03 1 1.19 2 1.12 0.96 0.98 0.94
*04:06 0 0.0 1 0.56 0.49 1.48 IND
*04:07 1 1.19 0 0.0 0.14 IND 0
*04:08 2 2.32 4 2.24 0.94 0.98 0.94
*04:09 1 1.19 1 0.56 0.58 0.73 0.47
*04:10 1 1.19 3 1.68 0.75 1.11 1.43
*04:11 4 4.76 6 3.37 0.57 0.87 0.69
*07:01 2 2.32 2 1.12 0.43 0.73 0.46
*08:01 2 2.32 3 1.68 0.69 0.88 0.7
*08:03 3 3.57 6 3.37 0.93 0.98 0.94
*08:04 0 0.0 2 1.12 0.32 1.48 IND
*08:07 0 0.0 2 1.12 0.32 1.48 IND
*09:01 0 0.0 2 1.12 0.32 1.48 IND
*10:01 0 0.0 1 0.56 0.49 1.48 IND
*11:01 4 4.76 5 2.80 0.73 0.92 0.77
*11:02 1 1.19 3 1.68 0.75 1.11 1.43
*11:03 1 1.19 3 1.68 0.75 1.11 1.43
*12:01 5 5.95 9 5.05 0.75 0.94 0.83
*12:02 4 4.76 1 0.56 0.96 0.98 0.94
*13:01 3 3.57 4 2.24 0.52 0.83 0.61
*13:02 4 4.76 1 0.56 0.01 0.44 0.29 0.11
*13:03 3 3.57 5 2.80 0.73 0.92 0.77
*13:04 0 0.0 1 0.56 0.49 1.48 IND
*13:06 1 1.19 3 1.65 0.75 1.11 1.43
*13:09 0 0.0 2 1.12 0.32 1.48 IND
*14:01 0 0.0 3 1.65 0.22 1.49 IND
*14:02 2 2.32 3 1.65 0.69 0.88 0.7
*14:05 1 1.19 9 5.05 0.11 1.36 4.61
*14:06 2 2.32 7 3.93 0.51 1.16 1.71
*15:01 2 2.32 9 5.05 0.3 1.23 2.25
*15:02 3 3.57 5 2.80 0.73 0.92 0.77
*15:03 7 8.33 9 5.05 0.28 0.81 0.56
*16:01 2 2.32 7 3.93 0.51 1.16 1.71
*16:02 3 3.57 8 4.49 0.72 1.08 1.28
*16:03 4 4.76 6 3.37 0.57 0.87 0.69
Total 84 178
Caption: B = Bonferroni, RR = Relative Risk, OD = Odds Ratio, IND = indeﬁnite.
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inﬂammation cytokines TNF-alfa, IL-1beta in patients subjected to
surgical removal of the hippocampus and that achieved seizure
control. These ﬁndings suggested the role of those cytokines in the
perpetuation of epileptic episodes in human patients with TLE-SH
[11,17]. As some HLA class II alleles are associated with a
susceptibility to inﬂammatory diseases characterized by the
increased expression of cytokines such as TNF-a and IL-1b, as
in TLE-SH [18], we have hypothesized that the HLA-DRB1, HLA-
DQB1, and HLA-DQA1 alleles might participate in the inﬂamma-
tory response to different antigens during the ﬁrst years of life,
eventually leading to TLE-SH in susceptible individuals. In the
present study, the DRB1*1302 (p = 0.01) allele was signiﬁcantly
correlated with susceptibility to TLE-SH; however, this signiﬁcance
was lost following Bonferroni correction. No previous study has
demonstrated an association of this allele with TLE-SH, either as a
protective or a susceptibility factor. Regarding HLA DR13 associa-
tion studies in other types of epilepsy, there has been no evidence
to indicate that susceptibility to juvenile myoclonic epilepsy (JME)
phenotype; and none of the investigated alleles or haplotypes
(DRB1*13:01-DQB1*06:03 or DRB1*13:02-DQB1*06:04) has exhib-
ited signiﬁcant differences between patients and controls as either
protective or susceptibility factors [19]. It is worth noting that thenatural history of JME is not characterized by IPI or progression,
which are present in most cases of TLE-SH, suggesting that tissue
reorganization and neuroplasticity may be orchestrated by local
phenomena.
Our results contrast from those reported by Ozkara et al. [14],
who were the only previous authors to analyze the role of HLA class
II alleles in TLE-SH. They have found a higher frequency of HLA-
DR4, HLA-DR7, and HLA-DQ2 in individuals with TLE-HS compared
with controls and thus suggesting that these alleles might be
involved in susceptibility to the disease. They concluded that these
haplotypes appear to behave as risk factors but are not essential for
the onset of disease. In our study, in addition to haplotypes, we also
analyzed the alleles in the HLA-DRB1, HLA-DQB1, and HLA-DQA1
regions separately but did not ﬁnd that their expression was
increased in individuals with TLE-SH compared with controls,
except for the tendency of HLA DRB1*1302 to behave as a
susceptibility factor. Some of the alleles investigated by Ozkara
et al., such as DQB1*02:02, which is part of the DQ2 region;
DRB1*04:11, *04:12, *04:04, *04:51, *04:52, *04:12, *04:13,
*04:14, *04:15, *04:16, *04:17, *04:18, *04:19, *04:20, *04:21,
*04:22, *04:23, *04:24, *04:25, *04:26, and *04:27, which form
region DR4; and DRB1*07:02, which forms region DR7, were not
found in either patients or controls in our study. We were unable to
Table 5
Distribution of HLA-DQB1 alleles identiﬁed by the high-resolution system.
Alleles Patients
(N = 42)
FR% Controls
(N = 89)
FR% p-value RR OR
*02:01 8 9.52 19 10.67 0.76 1.05 1.15
*02:03 2 2.38 6 3.37 0.65 1.11 1.45
*03:01 4 4.76 6 3.37 0.57 0.87 0.69
*03:02 3 3.57 5 2,80 0.73 0.92 0.77
*03:03 3 4.57 5 2.80 0.73 0.92 0.77
*03:04 5 5.95 8 4.49 0.6 0.9 0.73
*03:05 0 0.0 2 1.12 0.32 1.48 IND
*03:07 2 2.38 3 1.68 0.69 0.88 0.7
*04:01 10 11.90 15 8.42 0.34 0.86 0.65
*04:02 6 7.14 11 6.17 0.75 0.95 0.85
*05:01 8 9.52 14 7.86 0.63 0.92 0.79
*05:02 2 2.38 5 2.80 0.83 1.05 1.19
*05:03 6 7.14 9 5.05 0.48 0.87 0.68
*05:04 2 2.38 10 10.11 1.44 1.26 2.53
*06:01 2 2.38 3 1.68 0.69 0.88 0.7
*06:02 8 9.52 14 7.86 0.63 0.92 0.79
*06:03 5 5.95 9 5.05 0.75 0.94 0.83
*06:04 0 0.0 2 1.12 0.32 1.48 IND
*06:05 3 4.57 8 4.49 0.72 1.08 1.28
*06:06 0 0.0 3 1.68 0.22 1.49 IND
*06:07 0 0.0 3 1.68 0.22 1.49 IND
*06:08 2 2.38 9 5.05 0.3 1.23 2.25
*06:11 3 4.57 9 5.05 0.58 1.12 1.46
Total 84 178
Caption: RR = relative risk, OD = odds ratio, IND = indeﬁnite.
Table 6
Distribution of HLA-DQA1 alleles identiﬁed by the high-resolution system.
Allele Patients (N = 42) FR% Controls (N = 89) FR% p-value RR OR
*01:01
*01:02
*01:03
*01:04
*02:01
*03:01
*04:01
*05:01
*05:02
Total
10
8
9
7
12
8
8
16
6
84
11.90
9.52
10.71
8.33
14.28
9.58
9.58
19.04
7.14
18
13
14
8
17
24
23
42
19
178
10.11
7.30
7.86
4.49
9.55
13.48
12.92
23.59
10.67
0.87
0.51
0.42
0.19
0.35
0.32
0.24
0.32
0.33
1.02
0.9
0.88
0.76
0.87
1.14
1.17
1.12
1.15
1.08
0.73
0.68
0.49
0.67
1.57
1.74
1.45
1.63
Caption: RR = relative risk, OD = odds ratio, IND = indeﬁnite.
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the allelic regions obtained before high-resolution analysis.
We have attribute our ﬁndings and the loss of statistical
signiﬁcance of the HLA-DRB1*13:02 allele to the small number of
patients included in the study and to the fact that we have
analyzed samples of peripheral blood. We believe that the HLA-
DRB1*13:02 allele is a probable candidate for susceptibility to
TLE-SH due to its role in the recognition of autoantigens that
might interfere with the progression and morbidity of patients. As
the hippocampi of individuals with TLE-SH who were subjected to
surgery exhibit increased expression of HLA-DR, in addition to
increased numbers of macrophages in the microglial cells and
increased expression of IL-1ß in the astrocytic cells, we believe
that the aforementioned loss of statistical signiﬁcance was due
to transcriptional factors and the small sample size. Thus, a
role for HLA-DR alleles in the inﬂammatory mechanisms of
epilepsies appears to be supported by the results of histopatho-
logical studies [12,13].
Epilepsies are, as a whole, the result of multifactorial conditions
and interactions among multiple genes. Otherwise, the mechanism
of susceptibility mediated by HLA class I and the inﬂammatory
reaction by means of innate immunity during disease progressionmight explain the greater presence of macrophage inﬁltrate in the
resected tissue. This mechanism might also account for the fact
that we did not ﬁnd class II alleles associated with susceptibility to
TLE-SH, which may instead be correlated with HLA class I alleles.
This hypothesis is further supported by the results reported by
Nakahara et al. [20], who found increased numbers of CD4+ and
CD8+ T cells in hippocampi surgically removed from individuals
with TLE-SH. The number of these cells varied from one patient to
another, but overall, the number of CD8+ T cells was signiﬁcantly
higher than the number of CD4+ T cells. This higher number of
CD8+ T cells appears to support and justify the results we obtained.
Experimental induction of epileptic seizures in rodents was
associated with increased expression of molecules of major
histocompatibility complex (MHC) class I, the animal version of
the human HLA class I, in some brain areas several hours after
stimulation. Concurrently, regenerative processes are activated
and also appear to involve the participation of MHC class I
molecules [21].
Although the HLA class II system exhibits remarkable polymor-
phism and is involved in susceptibility to several diseases, our
ﬁndings may suggest that multiple factors may inﬂuence its
correlation, or lack thereof, with TLE-SH.
We conclude that genetic susceptibility to TLE-SH is not
determined by HLA class II alleles in the DRB1, DQB1, and DQA1
regions but that the HLA DRB1*1302 allele exhibited a tendency to
behave as a susceptibility factor for TLE-SH.
4.1. Perspectives and limitations of the present study
The small number of patients included may have been a
limitation to this study. Nevertheless, the innovative character of
high-resolution studies of genetic susceptibility involving genes
that are strong mediators of the inﬂammatory response may
contribute to genetic research aiming at elucidating the intricate
mechanism underlying TLE-SH.
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